Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

ClinicalTrials.gov ID: NCT00301236

Public ClinicalTrials.gov record NCT00301236. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 5-Week Treatment, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of the Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules Administered Once Daily in Pediatric Children With Attention-Deficit/Hyperactivity Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.

Study identification

NCT ID
NCT00301236
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis
Industry
Enrollment
252 participants

Conditions and interventions

Eligibility (public fields only)

Age range
6 Years to 12 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2006
Primary completion
Not listed
Completion
Oct 31, 2006
Last update posted
Dec 20, 2007

2006

United States locations

U.S. sites
25
U.S. states
18
U.S. cities
24
Facility City State ZIP Site status
Novartis Investigational Site Mesa Arizona 85210
Novartis Investigational Site Little Rock Arkansas 72205
Novartis Investigational Site Los Angeles California 90095
Novartis Investigational Site Boulder Colorado 80304
Novartis Investigational Site Maitland Florida 32751
Novartis Investigational Site Orlando Florida 32806
Novartis Investigational Site Stone Mountain Georgia 30083
Novartis Investigational Site Libertyville Illinois 60048
Novartis Investigational Site Overland Park Kansas 66211
Novartis Investigational Site Prairie Village Kansas 66206
Novartis Investigational Site Cambridge Massachusetts 02138
Novartis Investigational Site Las Vegas Nevada 89128
Novartis Investigational Site Piscataway New Jersey 08855
Novartis Investigational Site Toms River New Jersey 08755
Novartis Investigational Site New York New York 10029
Novartis Investigational Site New York New York 10032
Novartis Investigational Site Staten Island New York 10305
Novartis Investigational Site Chapel Hill North Carolina 27514
Novartis Investigational Site Raleigh North Carolina 27609
Novartis Investigational Site Columbus Ohio 43205
Novartis Investigational Site Gresham Oregon 97030
Novartis Investigational Site Philadelphia Pennsylvania 19149
Novartis Investigational Site Jackson Tennessee 38305
Novartis Investigational Site Memphis Tennessee 38119
Novartis Investigational Site Houston Texas 77007

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00301236, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 20, 2007 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00301236 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →